AstraZeneca pauses pandemic vaccine trial after one illness



by   |  VIEW 550

AstraZeneca pauses pandemic vaccine trial after one illness

AstraZeneca, the Cambridge-headquartered British-Swedish pharmaceutical and one of the front-runners in developing a vaccine for the ongoing pandemic outbreak in many tranches of the globe, put its Phase III human clinical trial for pandemic vaccine on a temporary hold after the company had experienced an illness of “unexplained nature” that came as a side-effect of the shots.

Besides, the British-Swedish pharmaceutical had also issued a statement late on Tuesday evening saying “The company’s standard review process triggered a pause to vaccination to allow review of safety data,” however, the vaccine-maker didn’t reveal any information regarding the nature of side-effect.

A health news website STAT had been the first to report the pause in AstraZeneca’s late-stage human trial, while the site had also added that the side effect had apparently occurred in United Kingdom. In tandem, later on the da a spokesperson for AstraZeneca had reaffirmed the temporary pause in the company’s vaccination trial in the United States alongside other countries.

Later last month, the British-Swedish drugmaker had enrolled as many as 30,000 Americans for its phase III clinical trial. Nonetheless, temporary setbacks or pauses in large-scale medical studies aren’t uncommon.

AstraZeneca pauses vaccine trial amid resurgence in pandemic cases

In factuality, latest remark from AstraZeneca to put a hold on its pandemic vaccine trial, which has been a major blow to optimisms over a pandemic vaccine as early as before the November 3 US Presidential election as touted by the US President Donald Trump, came forth shortly after nine vaccine makers across the globe such as Moderna, Sanofi, AstraZeneca, Pfizer, J&J and others had sent a public letter earlier on the day saying that a further quickening of the vaccine development process would not be possible given the scale of wide-ranging side-effects that could have emerged in the late-stage trials.

Nonetheless, AstraZeneca had also pointed out that the single event could be an illness arising from other diseases rather than the vaccine itself.